IVI-RMA Global (IVI-RMA), the largest medical group in the world specialising in assisted reproductive technologies, is looking to float on a stock exchange within 18 months.
Healthcare Markets International reported in early October that it had mandated Morgan Stanley to look after the sale of a 30% stake in the group. A flotation would be considered after that is complete.
Spanish newspaper Cinco Dias reports that there has been high interest among international funds for the stake and that a subsequent IPO would boost the company’s international growth and, in turn, to allow minority shareholders to divest.
IVI-RMA was formed out of a merger in February 2017 between the Valencian Infertility Institute (IVI) and Reproductive Medicine Associates of New Jersey (RMANJ).
Headed up by Richard Scott out of New Jersey in the US, IVI-RMA Global currently has more than 70 centres in 12 countries with practices in the US, Spain, Portugal, Italy, United Kingdom, Mexico, Panama, Argentina, Chile, Brazil, UAE and India.
The company is valued at around €1.2bn (US$1.3bn).